Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Laekna, Inc. ( (HK:2105) ) has provided an update.
Laekna, Inc. has announced the completion of patient enrollment for its Phase III clinical trial, AFFIRM-205, which is evaluating the efficacy and safety of LAE002 (afuresertib) combined with fulvestrant in treating HR+/HER2- locally advanced or metastatic breast cancer. The company aims to release topline data in the first half of 2026, with plans to submit a new drug application in China later that year. Additionally, Laekna has entered into an exclusive licensing agreement with Qilu Pharmaceutical Company Limited for the research, development, and commercialization of LAE002 in the China region.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company is engaged in research and development, particularly in the field of targeted therapies for various types of cancer.
Average Trading Volume: 4,123,283
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$6.63B
For an in-depth examination of 2105 stock, go to TipRanks’ Overview page.